Warning Letter — TXP Innovations LLC dba Tex Peptides
The FDA issued a warning letter to TXP Innovations LLC (dba Tex Peptides) regarding the distribution of unapproved and misbranded drug products. The Center for Drug Evaluation and Research (CDER) identified regulatory violations following an evaluation of the firm's practices.
This action affects TXP Innovations LLC, their distributors, and regulatory or compliance departments at firms manufacturing or marketing peptide-based products without FDA approval.
This issuance indicates continued CDER scrutiny of the peptide market, specifically targeting the sale of substances for therapeutic use that have not undergone the formal drug approval process. The citation for misbranding suggests that the FDA found the labeling lacked adequate directions for use, a common enforcement vector for firms attempting to market products under the guise of 'research only' while making clinical claims. Regulatory teams should interpret this as a signal that the agency is prioritizing enforcement against unapproved new drugs in the peptide space.
Review all digital marketing materials and product listings to ensure no unapproved therapeutic claims are present. Verify that all products intended for human use have been subjected to the appropriate New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) processes. Ensure that labeling provides adequate directions for use for all intended indications.
FDA Warning Letter issued to: TXP Innovations LLC dba Tex Peptides. 08/24/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026
Open in openFDA / FDA.gov